Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMVT Immunovant Inc
- Stocks
- Healthcare
- NASDAQ: IMVT
Price (delayed)
$15.34
Market cap
$2.62B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.73
Enterprise value
$1.91B
Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous
Highlights
The equity has soared by 101% from the previous quarter and by 15% YoY
Immunovant's debt has decreased by 29% YoY
IMVT's quick ratio has surged by 89% since the previous quarter but it is down by 21% year-on-year
IMVT's net income has plunged by 60% YoY and by 8% from the previous quarter
Immunovant's EPS has decreased by 45% YoY and by 4.2% QoQ
Key stats
What are the main financial stats of IMVT
Market
Valuations
Earnings
Shares outstanding
170.92M
Market cap
$2.62B
Enterprise value
$1.91B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.68
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$438.15M
Net income
-$413.84M
EBIT
-$412.95M
EBITDA
-$412.44M
Free cash flow
-$376.63M
Per share
Balance sheet
Liquidity
EPS
-$2.73
EPS diluted
-$2.73
Free cash flow per share
-$2.48
Book value per share
$4.16
Revenue per share
$0
TBVPS
$5.12
Total assets
$776.22M
Total liabilities
$68.78M
Debt
$98,000
Equity
$707.45M
Working capital
$698.89M
Debt to equity
0
Current ratio
11.16
Quick ratio
10.41
Net debt/EBITDA
1.73
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-71.9%
Return on equity
-80.6%
Return on invested capital
N/A
Return on capital employed
-58.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMVT stock price
How has the Immunovant stock price performed over time
Intraday
-0.65%
1 week
8.79%
1 month
-2.91%
1 year
-39.2%
YTD
-38.07%
QTD
-10.24%
Financial performance
How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$438.15M
Net income
-$413.84M
Gross margin
N/A
Net margin
N/A
IMVT's net income has plunged by 60% YoY and by 8% from the previous quarter
The operating income has dropped by 55% year-on-year and by 8% since the previous quarter
Price vs fundamentals
How does IMVT's price correlate with its fundamentals
Growth
What is Immunovant's growth rate over time
Valuation
What is Immunovant stock price valuation
P/E
N/A
P/B
3.68
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 45% YoY and by 4.2% QoQ
The equity has soared by 101% from the previous quarter and by 15% YoY
The stock's price to book (P/B) is 52% less than its last 4 quarters average of 7.7 and 42% less than its 5-year quarterly average of 6.3
Efficiency
How efficient is Immunovant business performance
IMVT's return on equity is down by 44% year-on-year and by 3.5% since the previous quarter
IMVT's return on assets is down by 40% year-on-year and by 3% since the previous quarter
Dividends
What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMVT.
Financial health
How did Immunovant financials performed over time
IMVT's quick ratio has surged by 89% since the previous quarter but it is down by 21% year-on-year
Immunovant's current ratio has surged by 85% QoQ but it has decreased by 19% YoY
Immunovant's debt is 100% lower than its equity
The equity has soared by 101% from the previous quarter and by 15% YoY
Immunovant's debt has decreased by 29% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.